TCGA-4H-AAAK-01A-12R-A41B-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- UV_RESPONSE_DN+0.310
- WNT_BETA_CATENIN_SIGNALING+0.290
- APICAL_JUNCTION+0.280
- TGF_BETA_SIGNALING+0.250
- APICAL_SURFACE+0.230
- COAGULATION+0.230
- MYOGENESIS+0.230
- HEDGEHOG_SIGNALING+0.220
- MYC_TARGETS_V2+0.200
Top 10 suppressed
- MTORC1_SIGNALING-0.440
- PROTEIN_SECRETION-0.430
- OXIDATIVE_PHOSPHORYLATION-0.390
- G2M_CHECKPOINT-0.330
- PEROXISOME-0.320
- ADIPOGENESIS-0.310
- E2F_TARGETS-0.310
- MYC_TARGETS_V1-0.310
- FATTY_ACID_METABOLISM-0.290
- HEME_METABOLISM-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.838 |
| 2 | s0122297 | — | — | 0.833 |
| 3 | 12305e97-f72f-4de7-9735-4cdbecb60296 | — | — | 0.826 |
| 4 | SRR8613760 | — | E | 0.826 |
| 5 | R116 | — | — | 0.822 |
| 6 | TCGA-55-8614-01A-11R-2403-07 | — | cohortSQ1 | 0.821 |
| 7 | SRR5088831 | — | — | 0.821 |
| 8 | TCGA-85-8350-01A-11R-2296-07 | — | cohortSQ1 | 0.820 |
| 9 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.820 |
| 10 | 3843de1d-0eaa-48af-be58-903fcf2e5f89 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |